Delcath Systems

Delcath Systems, Inc. (NASDAQ- DCTH) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. Our proprietary product---Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. Delcath is in late-stage clinical development in the United States with initial commercial activities in Europe, where the Melphalan/HDS is marketed as a CE Marked device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). Our commercial strategy for CHEMOSAT is to steadily grow clinical adoption in...

Oncology,research & development,liver cancers,ocular melanoma,intrahepatic cholangiocarcinoma,hepatocellular carcinoma,uveal melanoma,metastatic uveal melanoma,hepatic dominant uveal melanoma,and liver directed therapy

Delcath systems operates in the Pharmaceutical manufacturing industry.

Delcath systems's revenue is 11m - 100m

Delcath systems has 51 - 200 employees.